The company has been marketing the CellerateRx brand of products within the US to the human health care market. CellerateRx is available in two forms, a powder and a gel, and both products feature HCPCS codes for reimbursement in the US.
Scott Haire, chairman of MB Software (MBSB), said: “These enhanced agreements coupled with our recent announcement of evidence-based studies on the Cellerate products will give us greater momentum going into 2008 and beyond.”